Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

NCT06441110 | Recruiting Phase 3

• 1 other identifier: 2023XHYG0045-02
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer. However, research on the combination of tislelizumab and BCG for bladder cancer treatment has largely been retrospective. Currently, ongoing clinical trials have not discussed the effectiveness of PD-1/PD-L1 inhibitors combined with BCG instillation in reducing postoperative recurrence in intermediate-risk NMIBC. Therefore, this study aims to explore the clinical efficacy and safety of tislelizumab combined with BCG in the treatment of intermediate and high-risk NMIBC. For this purpose, investigators have established strict screening criteria to include eligible patients in the study and have recruited suitable patients from multiple medical centers.Investigators have also developed a meticulous implementation process and follow-up considerations, hoping to better verify the clinical efficacy and safety of the combined use of these two drugs.

Conditions

Urinary Bladder Neoplasms; BCG Vaccine; Immunotherapy, Active; Multicenter Study; Treatment Outcome; Neoplasm Recurrence, Local

Outcome Measures

Primary Outcomes (1)

• Relapse-Free Survival(RFS)

  The time from postoperative cystoscopic examination to the first documented recurrence of bladder tumor.

  From date of postoperative cystoscopic examination to the first documented recurrence of bladder tumor,assessed up to 60 months.

Secondary Outcomes (3)

• Progression-Free Survival(PFS)

  From date of postoperative cystoscopic and pathological examinations to the first progression of bladder tumor, assessed up to 60 months.

• Overall survival

  From date of post-surgery to the time of death due to any cause,assessed up to 60 months

• Adverse event（AS)

  From date of post-surgery to the time of death due to any cause,assessed up to 60 months.

Study Arms (1)

Postoperative Instillation Therapy Group

EXPERIMENTAL

Tislelizumab in Combination with Bacillus Calmette-Guérin for the Treatment of Intermediate and High-Risk NMIBC Group

Drug: Tislelizumab in Combination with Bacillus Calmette-Guérin

Interventions

Tislelizumab in Combination with Bacillus Calmette-Guérin DRUG

Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.

Postoperative Instillation Therapy Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary participation in the trial with signed informed consent;
• Patients aged ≥18 and ≤75 years, regardless of gender, with an expected survival of ≥2 years;
• Histologically confirmed non-muscle-invasive bladder urothelial carcinoma with positive PD-L1 expression. According to the 2014 guidelines of the Chinese Urological Association (CUA), patients are assessed as having a medium to high risk of recurrence or progression. (For patients considering a second transurethral resection, they may be included in the study after completing the procedure and if pathology confirms medium to high risk non-muscle-invasive bladder urothelial carcinoma);
• Performance status score (Eastern Cooperative Oncology Group, ECOG) of 0-2;
• Completion of screening-related examinations (complete blood count, coagulation function, liver and kidney function, infectious disease screening, 12-lead ECG, urinary system ultrasound, pelvic MR, and tissue pathology examination), without surgical contraindications.

You may not qualify if:

• Any of the following conditions:
• Immune deficiency or impairment (such as AIDS patients), current use of immunosuppressive drugs or radiation therapy that may cause systemic BCG disease reaction; allergy to BCG components; patients with fever and acute infectious diseases, including active tuberculosis or those undergoing anti-tuberculosis treatment; those with severe chronic cardiovascular or cerebrovascular diseases or chronic kidney disease;
• Concurrent urogenital system tumors or tumors in other organs;
• Muscle-invasive bladder urothelial carcinoma (stage T2 and above) patients;
• Patients who have received chemotherapy, radiotherapy, or immunotherapy within the past 4 weeks (except immediate postoperative bladder instillation chemotherapy);
• Pregnant or lactating women, women of childbearing age not using effective contraception, or those planning to conceive during the trial period (including male participant partners);
• Known or suspected intraoperative bladder perforation;
• Presence of gross hematuria prior to enrollment, suspected unhealed surgical wounds or damaged urinary mucosa;
• Severe urethral stricture preventing cystoscopy, history of bladder contracture, or functional bladder volume less than 100mL;
• Accompanying cystitis, or those who have received other bladder instillation medications and have severe bladder irritation signs expected to affect the assessment of this study;
• Patients with various mental disorders, severe coagulation function, liver and kidney function, hematopoietic function disorders, etc., that cannot tolerate surgical treatment;
• Participation in other drug clinical trials within 3 months before enrollment;
• Known or suspected opioid or alcohol dependence;
• Any condition that the researcher believes may increase the risk to the participant or interfere with the execution of the clinical trial.

Sponsors & Collaborators

• Fujian Medical University Union Hospital: lead

Study Sites (1)

Department of Urology, Fujian Union Hospital, Fujian Medical University

Fuzhou, Fujian, 350000, China

RECRUITING

MeSH Terms

Conditions

Urinary Bladder Neoplasms; Motor Activity; Neoplasm Recurrence, Local

Interventions

tislelizumab

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases; Behavior; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Zhenlin Chen

  Department of Urology, Fujian Union Hospital, Fujian Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jiabing Zheng

CONTACT

+8613799422519; xhyykjk@163.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2024
• First Posted: June 4, 2024
• Study Start: June 1, 2023
• Primary Completion: June 1, 2025
• Study Completion (Estimated): June 1, 2035
• Last Updated: June 4, 2024

Record last verified: 2024-04

Locations

CN (1)